<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JRA</journal-id>
<journal-id journal-id-type="hwp">spjra</journal-id>
<journal-id journal-id-type="nlm-ta">J Renin Angiotensin Aldosterone Syst</journal-id>
<journal-title>Journal of the Renin-Angiotensin-Aldosterone System</journal-title>
<issn pub-type="ppub">1470-3203</issn>
<issn pub-type="epub">1752-8976</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1470320312448950</article-id>
<article-id pub-id-type="publisher-id">10.1177_1470320312448950</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Preeclampsia and angiotensin converting enzyme (ACE) I/D and angiotensin II type-1 receptor (AT1R) A1166C polymorphisms: association with ACE I/D polymorphism</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Rahimi</surname><given-names>Zohreh</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312448950">1</xref>
<xref ref-type="aff" rid="aff2-1470320312448950">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Rahimi</surname><given-names>Ziba</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312448950">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mozafari</surname><given-names>Hadi</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312448950">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Parsian</surname><given-names>Abbas</given-names></name>
<xref ref-type="aff" rid="aff3-1470320312448950">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-1470320312448950"><label>1</label>Medical Biology Research Center, Kermanshah University of Medical Sciences, Iran</aff>
<aff id="aff2-1470320312448950"><label>2</label>Department of Biochemistry, Medical School, Kermanshah University of Medical Sciences, Iran</aff>
<aff id="aff3-1470320312448950"><label>3</label>Division of Neuroscience and Behavior, NIAAA, National Institutes of Health, USA</aff>
<author-notes>
<corresp id="corresp1-1470320312448950">Zohreh Rahimi, Medical Biology Research Center, Medical School, Daneshgah Avenue, Kermanshah, PO Box 67148-69914, Iran. Email: <email>zrahimi@kums.ac.ir</email>, <email>rahimizus@yahoo.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>14</volume>
<issue>2</issue>
<fpage>174</fpage>
<lpage>180</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1470320312448950">
<title>Background:</title>
<p>The aim of the present study was to investigate the association between angiotensin converting enzyme (ACE) insertion/deletion (I/D) and angiotensin II type-1 receptor (AT1R) A1166C polymorphisms with the risk of preeclampsia and lipid peroxidation in preeclamptic women from Western Iran.</p>
</sec>
<sec id="section2-1470320312448950">
<title>Methods:</title>
<p>One hundred and ninety-eight preeclamptic women (128 women with mild and 70 with severe forms) and 100 age- and parity-matched controls were enrolled in this case-control study.</p>
</sec>
<sec id="section3-1470320312448950">
<title>Results:</title>
<p>The presence of D allele of ACE was associated with a 1.8-fold increased risk of preeclampsia (<italic>p</italic>=0.002) in total preeclamptic patients. The frequency of AT1R AC+CC genotypes was higher in mild preeclamptic women (32%) compared to controls (27.2%) (<italic>p</italic>&gt;0.05). In mild preeclamptic women with ID genotype, the level of total antioxidant capacity (TAC) was significantly decreased compared to those with II genotype. Also, there was a trend toward increasing malondialdehyde (MDA) and decreasing TAC levels in mild and severe preeclamptic women with AT1R AA through CC genotypes.</p>
</sec>
<sec id="section4-1470320312448950">
<title>Conclusions:</title>
<p>Our study indicates that lipid peroxidation and oxidative stress are involved in the development of preeclampsia that might be influenced by polymorphism in the renin-angiotensin-aldosterone system genes.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Preeclampsia</kwd>
<kwd>ACE I/D</kwd>
<kwd>AT1R A1166C</kwd>
<kwd>MDA</kwd>
<kwd>TAC</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section5-1470320312448950" sec-type="intro">
<title>Introduction</title>
<p>Preeclampsia that is defined as a complication of pregnancy has an incidence of 2%–5% in most parts of the world. It is a multifactorial disorder that results from complex interactions between genetic and environmental factors.<sup><xref ref-type="bibr" rid="bibr1-1470320312448950">1</xref>,<xref ref-type="bibr" rid="bibr2-1470320312448950">2</xref></sup> Preeclampsia is associated with increased blood pressure and proteinuria after 20 weeks of gestation.<sup><xref ref-type="bibr" rid="bibr3-1470320312448950">3</xref></sup></p>
<p>During normal pregnancy, because of the stimulation of the renin-angiotensin-aldosterone system (RAAS), the plasma levels of renin and aldosterone are increased.<sup><xref ref-type="bibr" rid="bibr4-1470320312448950">4</xref></sup> In preeclamptic women there is suppression of the RAAS system and increased vascular resistance and failure to develop the physiologic hypervolemia of pregnancy.<sup><xref ref-type="bibr" rid="bibr1-1470320312448950">1</xref></sup> The angiotensin converting enzyme (ACE) is a key RAAS component and plays an important role in blood pressure homeostasis by generating the vasoconstrictor peptide angiotensin II and by inactivating the vasodilator peptides bradykinin and Ang-(1-7).<sup><xref ref-type="bibr" rid="bibr5-1470320312448950">5</xref></sup> Angiotensin II, which results from enzymatic reaction of ACE on angiotensin I, binds to angiotensin II type-1 receptor (AT1R). Enhanced activity of the angiotensin II-AT1R axis might contribute to the complications of preeclampsia.</p>
<p>An insertion/deletion (I/D) polymorphism of the angiotensin II-converting enzyme (ACE) gene has been reported to be associated with the highest serum ACE activity in individuals with D/D genotype, while subjects with the I/I genotype have the lowest ACE expression.<sup><xref ref-type="bibr" rid="bibr6-1470320312448950">6</xref></sup> This polymorphism also has been associated with hypertension and diabetic nephropathy.<sup><xref ref-type="bibr" rid="bibr6-1470320312448950">6</xref>,<xref ref-type="bibr" rid="bibr7-1470320312448950">7</xref></sup> There are controversial reports from different populations related to the role of ACE I/D polymorphism in the pathogenesis of preeclampsia.<sup><xref ref-type="bibr" rid="bibr1-1470320312448950">1</xref>,<xref ref-type="bibr" rid="bibr3-1470320312448950">3</xref>,<xref ref-type="bibr" rid="bibr8-1470320312448950">8</xref><xref ref-type="bibr" rid="bibr9-1470320312448950"/>
<xref ref-type="bibr" rid="bibr10-1470320312448950"/>
<xref ref-type="bibr" rid="bibr11-1470320312448950"/>
<xref ref-type="bibr" rid="bibr12-1470320312448950"/>
<xref ref-type="bibr" rid="bibr13-1470320312448950"/>
<xref ref-type="bibr" rid="bibr14-1470320312448950"/>
<xref ref-type="bibr" rid="bibr15-1470320312448950"/>
<xref ref-type="bibr" rid="bibr16-1470320312448950"/>–<xref ref-type="bibr" rid="bibr17-1470320312448950">17</xref></sup> Also, in a few studies the association of AT1R A1166C polymorphism with preeclampsia has been examined.<sup><xref ref-type="bibr" rid="bibr8-1470320312448950">8</xref><xref ref-type="bibr" rid="bibr9-1470320312448950"/>–<xref ref-type="bibr" rid="bibr10-1470320312448950">10</xref>,<xref ref-type="bibr" rid="bibr17-1470320312448950">17</xref></sup> A positive relationship between the degree of oxidative stress and the clinical severity of preeclampsia has been reported, suggesting that the toxic effects of lipoperoxide lead to hypertension, endothelial damage and leukocyte activation.<sup><xref ref-type="bibr" rid="bibr18-1470320312448950">18</xref></sup></p>
<p>Recently, we reported that the frequency of preeclampsia in a referral hospital of Kermanshah University of Medical Sciences was 7.5%.<sup><xref ref-type="bibr" rid="bibr19-1470320312448950">19</xref></sup> The aim of the current study was to examine the influence of ACE I/D, AT1R A1166C polymorphisms and lipid peroxidation on the susceptibility to preeclampsia in a Kurdish population from Western Iran.</p>
</sec>
<sec id="section6-1470320312448950" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section7-1470320312448950">
<title>The sample</title>
<p>One hundred and ninety-eight preeclamptic women consisting of 128 women with mild and 70 with severe forms of preeclampsia with the mean age of 29±5.7 and 29.3±6.4 years, respectively, and 100 age- and parity-matched controls were enrolled in a case-control study. The patients were selected from the obstetric clinic of the Imam Reza Hospital of Kermanshah University of Medical Sciences. The patients were all preeclamptic women who were referred to the hospital, except those with multiple-birth pregnancy, previous hypertension, diabetes, cardiac and renal diseases. The ethnicity of the sample was determined to be Kurdish. Early-onset preeclampsia (before 34 weeks’ gestation) was diagnosed in 23 preeclamptic women, 19 with severe and four with mild preeclampsia; 175 cases were diagnosed as late-onset preeclampsia (after 34 weeks’ gestation).</p>
<p>The criteria for defining preeclampsia were systolic blood pressure equal or higher than 140 mmHg, diastolic blood pressure equal or higher than 90 mmHg, presence of proteinuria by 24-hour urinary excretion exceeding 300 mg, a urine protein: creatinine ratio of &gt;0.3 and equal or higher than 30 mg/dl protein in a random urine sample (1+ reaction on a standard urine dipstick). Severe preeclampsia was defined as blood pressure more than 160/110 mmHg, proteinuria &gt;3+, headache, visual disturbances, upper abdominal pain, serum creatinine and transaminase elevation, thrombocytopenia and fetal-growth restriction.<sup><xref ref-type="bibr" rid="bibr20-1470320312448950">20</xref></sup></p>
<p>Informed written consent was obtained from each individual before participation in the study. The study was approved by the Ethics Committee of Kermanshah University of Medical Sciences and was in accordance with the principles of the Declaration of Helsinki II.</p>
</sec>
<sec id="section8-1470320312448950">
<title>Genotype analysis</title>
<p>Extraction of DNA from leukocytes was performed using the phenol-chloroform method as previously described.<sup><xref ref-type="bibr" rid="bibr21-1470320312448950">21</xref></sup> The polymorphism of ACE I/D was detected by polymerase chain reaction (PCR) as previously described.<sup><xref ref-type="bibr" rid="bibr22-1470320312448950">22</xref></sup> The AT1R A1166C polymorphism was detected using PCR-restriction fragment length polymorphism (RFLP). The PCR included the forward primer of 5’ AAAAGCC AAATCCCACTCAA-3’, and the reverse primer of 5′-CAGGACAAAAGCAGGCTAGG-3′. The PCR products were digested with 1.5 U of Dde I restriction enzyme. The presence of AT1R 1166A allele produces 58- and 374-bp fragments while the AT1R 1166C allele results in 58-, 143- and 231-bp fragments.<sup><xref ref-type="bibr" rid="bibr17-1470320312448950">17</xref></sup></p>
</sec>
<sec id="section9-1470320312448950">
<title>Biochemical analysis</title>
<p>Serum total cholesterol (TC) and triglycerides (TG) were measured by the standard enzymatic method (Pars Azmon kit, Iran) using an automated RA-1000 (Technicon, USA). The serum low-density lipoprotein-cholesterol (LDL-C) and high-density lipoprotein-cholesterol (HDL-C) levels were measured using commercially available enzyme assay kits (Pars Azmon kit, Iran).</p>
<p>Serum total antioxidant capacity (TAC) levels were measured using commercially available kits (Randox Laboratories Ltd., Ireland NX2332). The concentration of malondialdehyde (MDA) in serum was measured as MDA- thiobarbituric acid (TBA) adduct using fluorescence detector by a highly specific, sensitive and reproducible method of high-performance liquid chromatography (HPLC) as previously described by Agarwal.<sup><xref ref-type="bibr" rid="bibr23-1470320312448950">23</xref></sup></p>
</sec>
<sec id="section10-1470320312448950">
<title>Statistical analysis</title>
<p>The allelic frequencies were calculated by the chromosome counting method. The significance of differences in genotype and allele frequencies of ACE and AT1R polymorphisms between patients and controls were calculated using the χ<sup>2</sup> test. Odds ratios (OR) were calculated as estimates of relative risk for disease, and 95% confidence intervals (CI) were obtained by SPSS logistic regression software. A two-tailed student’s <italic>t</italic> test was used to compare quantitative data. The generalized odds ratio (OR<sub>G</sub>) was calculated to find the association between disease status (disease vs. healthy or disease progression) and genotype according to the method suggested by Zintzaras et al.<sup><xref ref-type="bibr" rid="bibr24-1470320312448950">24</xref></sup> Statistical significance was assumed at the <italic>p</italic>&lt;0.05 level. The SPSS statistical software package version 16 was used for the statistical analysis.</p>
</sec>
</sec>
<sec id="section11-1470320312448950" sec-type="results">
<title>Results</title>
<p>The biochemical parameters of preeclamptic and healthy pregnant women are demonstrated in <xref ref-type="table" rid="table1-1470320312448950">Table 1</xref>.</p>
<table-wrap id="table1-1470320312448950" position="float">
<label>Table 1.</label>
<caption>
<p>The demographic and biochemical characteristics of preeclamptic and control women.</p>
</caption>
<graphic alternate-form-of="table1-1470320312448950" xlink:href="10.1177_1470320312448950-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Variables</th>
<th align="left">Mild preeclampsia (<italic>n</italic>=128)</th>
<th align="left">Severe preeclampsia (<italic>n</italic>=70)</th>
<th align="left">Healthy pregnant women (<italic>n</italic>=100)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>29±5.7</td>
<td>29.3±6.4</td>
<td>27.4±6.4</td>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>=0.128</td>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>=0.121</td>
<td/>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">b</xref></sup><italic>p</italic>=0.944</td>
<td/>
<td/>
</tr>
<tr>
<td>Pregnancy BMI (Kg/m<sup>2</sup>)</td>
<td>31.8±4.8</td>
<td>31.1±4.1</td>
<td>23.2±2.9</td>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>&lt;0.001</td>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>&lt;0.001</td>
<td/>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">b</xref></sup><italic>p</italic>=0.21</td>
<td/>
<td/>
</tr>
<tr>
<td>Gestational age (weeks)</td>
<td>30–39</td>
<td>30–39</td>
<td>36–39</td>
</tr>
<tr>
<td>Blood pressure (mmHg)</td>
<td>140.5±11.9</td>
<td>163.2±17.6</td>
<td>113.2±9.4</td>
</tr>
<tr>
<td>Systolic</td>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>&lt;0.001</td>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>&lt;0.001</td>
<td>74.3±7.4</td>
</tr>
<tr>
<td>Diastolic</td>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">b</xref></sup><italic>p</italic>&lt;0.001</td>
<td>102.7±9.7</td>
<td/>
</tr>
<tr>
<td/>
<td>87.5±7.8</td>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>&lt;0.001</td>
<td/>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>&lt;0.001</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">b</xref></sup><italic>p</italic>&lt;0.001</td>
<td/>
<td/>
</tr>
<tr>
<td>Proteinuria</td>
<td>28 (21.9)</td>
<td>0 (0)</td>
<td>0</td>
</tr>
<tr>
<td>Trace</td>
<td>66 (51.6)</td>
<td>0 (0)</td>
<td>0</td>
</tr>
<tr>
<td>Cases with 1<sup>+</sup>, <italic>n</italic> (%)</td>
<td>34 (26.5)</td>
<td>70 (100)</td>
<td>0</td>
</tr>
<tr>
<td>Cases with 2<sup>+</sup>-4<sup>+</sup>, <italic>n</italic> (%)</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>AST (U/L)</td>
<td>28.6±23.2</td>
<td>41.7±42.5</td>
<td>24.2±7.7</td>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>=0.29</td>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>&lt;0.001</td>
<td/>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">b</xref></sup><italic>p</italic>=0.002</td>
<td/>
<td/>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>22.6±29.2</td>
<td>32.9±39</td>
<td>18.4±6.9</td>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>=0.42</td>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>&lt;0.001</td>
<td/>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">b</xref></sup><italic>p</italic>=0.027</td>
<td/>
<td/>
</tr>
<tr>
<td>ALP (U/L)</td>
<td>336.3±144.2</td>
<td>376.9±205</td>
<td>218±67.6</td>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>&lt;0.001</td>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>&lt;0.001</td>
<td/>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">b</xref></sup><italic>p</italic>=0.11</td>
<td/>
<td/>
</tr>
<tr>
<td>Bilirubin (mg/dl)</td>
<td>0.53±0.26</td>
<td>0.59±0.28</td>
<td>0.47±0.36</td>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>=0.23</td>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>&lt;0.001</td>
<td/>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">b</xref></sup><italic>p</italic>=0.12</td>
<td/>
<td/>
</tr>
<tr>
<td>Total cholesterol (mg/dl)</td>
<td>233.2±53.1</td>
<td>251.9±70.9</td>
<td>248.3±45.7</td>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>=0.1</td>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>=0.91</td>
<td/>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">b</xref></sup><italic>p</italic>=0.06</td>
<td/>
<td/>
</tr>
<tr>
<td>TG (mg/dl)</td>
<td>176.9±28.7</td>
<td>181.7±36.6</td>
<td>164.7±30.5</td>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>=0.01</td>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>=0.002</td>
<td/>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">b</xref></sup><italic>p</italic>=0.56</td>
<td/>
<td/>
</tr>
<tr>
<td>HDL-C (mg/dl)</td>
<td>55.1±11.6</td>
<td>55.2±12.4</td>
<td>55.9±9.4</td>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>=0.85</td>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>=0.93</td>
<td/>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">b</xref></sup><italic>p</italic>=0.99</td>
<td/>
<td/>
</tr>
<tr>
<td>LDL-C (mg/dl)</td>
<td>133.2±34.6</td>
<td>140.1±36.6</td>
<td>140±26.2</td>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>=0.26</td>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>=1.0</td>
<td/>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">b</xref></sup><italic>p</italic>=0.33</td>
<td/>
<td/>
</tr>
<tr>
<td>Total antioxidant capacity (mmol/l)</td>
<td>1.33±0.25</td>
<td>1.38±0.19</td>
<td>1.39±0.17</td>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>=0.09</td>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>=0.91</td>
<td/>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">b</xref></sup><italic>p</italic>=0.3</td>
<td/>
<td/>
</tr>
<tr>
<td>MDA (µM)</td>
<td>9.8±3.7</td>
<td>10.9±4.6</td>
<td>5.8±2.2</td>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>&lt;0.001</td>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">a</xref></sup><italic>p</italic>&lt;0.001</td>
<td/>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn1-1470320312448950">b</xref></sup><italic>p</italic>=0.08</td>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1470320312448950">
<p><sup>a</sup>: comparison to healthy pregnant women; <sup>b</sup>: Comparison to severe preeclamptic women; BMI: body mass index; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; MDA: malondialdehyde.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The distribution of ACE genotypes and alleles in preeclamptic women and controls is depicted in <xref ref-type="table" rid="table2-1470320312448950">Table 2</xref>.</p>
<table-wrap id="table2-1470320312448950" position="float">
<label>Table 2.</label>
<caption>
<p>The distribution of angiotensin converting enzyme insertion/deletion (ACE I/D) genotypes and alleles in preeclamptic women and controls.</p>
</caption>
<graphic alternate-form-of="table2-1470320312448950" xlink:href="10.1177_1470320312448950-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Mild preeclamptic women (<italic>n</italic>=128)</th>
<th align="left">Severe preeclamptic women (<italic>n</italic>=70)</th>
<th align="left">Total preeclampsia (<italic>n</italic>=198)</th>
<th align="left">Healthy pregnant women (<italic>n</italic>=100)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE genotypes</td>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td>II</td>
<td>14 (10.9%)</td>
<td>11 (15.7%)</td>
<td>25 (12.6%)</td>
<td>16 (16%)</td>
</tr>
<tr>
<td>ID</td>
<td>33 (25.8%)</td>
<td>16 (22.9%)</td>
<td>49 (24.7%)</td>
<td>42 (42%)</td>
</tr>
<tr>
<td>DD</td>
<td>81 (63.3%)</td>
<td>43 (61.4%)</td>
<td>124 (62.7%)</td>
<td>42 (42%)</td>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn2-1470320312448950">a</xref></sup>(χ<sup>2</sup>=12.1, df=2, <italic>p</italic>=0.002)</td>
<td><sup><xref ref-type="table-fn" rid="table-fn2-1470320312448950">a</xref></sup>(χ<sup>2</sup>=8.3, df=2, <italic>p</italic>=0.016)</td>
<td><sup><xref ref-type="table-fn" rid="table-fn2-1470320312448950">a</xref></sup>(χ<sup>2</sup>=12.1, df=2, <italic>p</italic>=0.002)</td>
<td/>
</tr>
<tr>
<td>ACE alleles</td>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td>I</td>
<td>61 (23.8%)</td>
<td>38 (27.1%)</td>
<td>99 (25%)</td>
<td>74 (37%)</td>
</tr>
<tr>
<td>D</td>
<td>195 (76.2%)</td>
<td>102 (72.9%)</td>
<td>297 (75%)</td>
<td>126 (63%)</td>
</tr>
<tr>
<td/>
<td><sup><xref ref-type="table-fn" rid="table-fn2-1470320312448950">a</xref></sup>(χ<sup>2</sup>=11.1, df=1, <italic>p</italic>=0.001)</td>
<td><sup><xref ref-type="table-fn" rid="table-fn2-1470320312448950">a</xref></sup>(χ<sup>2</sup>=4, df=1, <italic>p</italic>=0.045)</td>
<td><sup><xref ref-type="table-fn" rid="table-fn2-1470320312448950">a</xref></sup>(χ<sup>2</sup>=10.1, df=1, <italic>p</italic>=0.002)</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1470320312448950">
<p><sup>a</sup>: comparison to healthy pregnant women; df: degree of freedom.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The frequency of ACE D/D genotype in mild, severe and total preeclamptic women was 63.3, 61.4 and 62.7%, respectively, compared to 42% in controls (<italic>p</italic>=0.002). As illustrated in <xref ref-type="table" rid="table2-1470320312448950">Table 2</xref>, the frequency of D allele of ACE was significantly higher in total preeclamptic women (75%) compared to healthy pregnant women (63%). As depicted in <xref ref-type="table" rid="table3-1470320312448950">Table 3</xref>, the presence of D allele of ACE was associated with a 1.8-fold increased risk of preeclampsia (<italic>p</italic>=0.002) in all preeclamptic patients.</p>
<table-wrap id="table3-1470320312448950" position="float">
<label>Table 3.</label>
<caption>
<p>The odds ratios (ORs) of ACE genotypes and alleles with respect to II genotype or I allele, respectively, in mild, severe and total preeclamptic women.</p>
</caption>
<graphic alternate-form-of="table3-1470320312448950" xlink:href="10.1177_1470320312448950-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Mild preeclampsia ORs (95% CI)</th>
<th align="left">Severe preeclampsia ORs (95% CI)</th>
<th align="left">Total preeclampsia ORs (95% CI)</th>
<th align="left">Healthy pregnant women</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE genotypes</td>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td>II</td>
<td>Reference group (<italic>n</italic>=14)</td>
<td>Reference group (<italic>n</italic>=11)</td>
<td>Reference group (<italic>n</italic>=25)</td>
<td>Reference group (<italic>n</italic>=16)</td>
</tr>
<tr>
<td>DD</td>
<td>2.34 (1.04–5.3, <italic>p</italic>=0.04, <italic>n</italic>=82)</td>
<td>1.56 (0.65–3.8, <italic>p</italic>=0.32, <italic>n</italic>=43)</td>
<td>1.89 (0.9–3.9, <italic>p</italic>=0.08, <italic>n</italic>=124)</td>
<td><italic>n</italic>=42</td>
</tr>
<tr>
<td>ACE alleles</td>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td>I</td>
<td>Reference group (<italic>n</italic>=60)</td>
<td>Reference group (<italic>n</italic>=39)</td>
<td>Reference group (<italic>n</italic>=99)</td>
<td>Reference group (<italic>n</italic>=75)</td>
</tr>
<tr>
<td>D</td>
<td>1.99 (1.3–3, <italic>p</italic>=0.001, <italic>n</italic>=196)</td>
<td>1.61 (1–2.6, <italic>p</italic>=0.046, <italic>n</italic>=103)</td>
<td>1.8 (1.3–2.6, <italic>p</italic>=0.002, <italic>n</italic>=297)</td>
<td><italic>n</italic>=125</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1470320312448950">
<p>CI: confidence interval; ACE: angiotensin converting enzyme.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In mild preeclamptic women, the presence of D allele significantly increased the risk of preeclampsia (OR=1.99, 95% CI=1.3-3, <italic>p</italic>=0.001). Also, the presence of this allele increased the risk of severe preeclampsia by 1.61 fold (<italic>p</italic>=0.046) as presented in <xref ref-type="table" rid="table3-1470320312448950">Table 3</xref>. In <xref ref-type="table" rid="table4-1470320312448950">Table 4</xref>, the distribution of AT1R A1166C genotypes and alleles is demonstrated.</p>
<table-wrap id="table4-1470320312448950" position="float">
<label>Table 4.</label>
<caption>
<p>The distribution of AT1R genotypes and alleles in preeclamptic and control women.</p>
</caption>
<graphic alternate-form-of="table4-1470320312448950" xlink:href="10.1177_1470320312448950-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Mild preeclampsia <italic>n</italic>=122</th>
<th align="left">Severe preeclampsia <italic>n</italic>=59</th>
<th align="left">Total preeclampsia <italic>n</italic>=181</th>
<th align="left">Controls <italic>n</italic>=92</th>
</tr>
</thead>
<tbody>
<tr>
<td>AT1R genotypes</td>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td>AA</td>
<td>83 (68%)</td>
<td>46 (78%)</td>
<td>129 (71.3%)</td>
<td>67 (72.8%)</td>
</tr>
<tr>
<td>AC</td>
<td>36 (29.5%)</td>
<td>13 (22%)</td>
<td>49 (27.1%)</td>
<td>21 (22.8%)</td>
</tr>
<tr>
<td>CC</td>
<td>3 (2.5%)</td>
<td>0 (0%)</td>
<td>3 (1.6%)</td>
<td>4 (4.4%)</td>
</tr>
<tr>
<td>AC+CC</td>
<td>39 (32%)</td>
<td>13 (22%)</td>
<td>52 (28.7%)</td>
<td>25 (27.2%)</td>
</tr>
<tr>
<td>OR [(95% CI, <italic>p</italic>)]</td>
<td>[1.3 (0.7–2.3, <italic>p</italic>=0.44)]</td>
<td>[0.75 (0.4–1.6, <italic>p</italic>=0.47)]</td>
<td>[1.08 (0.6–1.9, <italic>p</italic> =0.78)]</td>
<td/>
</tr>
<tr>
<td>AT1R alleles</td>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td>A</td>
<td>202 (82.8%)</td>
<td>105 (89%)</td>
<td>307 (84.8%)</td>
<td>155 (84.2%)</td>
</tr>
<tr>
<td>C</td>
<td>42 (17.2%)</td>
<td>13 (11%)</td>
<td>55 (15.2%)</td>
<td>29 (15.8%)</td>
</tr>
<tr>
<td>OR [(95% CI, <italic>p</italic>)]</td>
<td>[1.16 (0.7–1.95, <italic>p</italic>=0.57)]</td>
<td>[0.67 (0.3–1.4, <italic>p</italic>=0.27)]</td>
<td>[0.96 (0.6–1.6, <italic>p</italic>=0.86)]</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1470320312448950">
<p>AT1R: angiotensin II type-1 receptor; OR: odds ratio; CI: confidence interval.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>As shown in this table, the frequency of AC+CC genotypes was higher in mild and total preeclamptic women (32 and 28.7%, respectively) compared to controls (27.2%) (<italic>p</italic>&gt;0.05). A higher frequency for C allele of AT1R (17.2%) was observed in mild preeclamptic women compared to controls (15.8%) (OR=1.16 (95% CI=0.69–1.95, <italic>p</italic>=0.57) (<xref ref-type="table" rid="table4-1470320312448950">Table 4</xref>). We examined the effect of interaction between ACE D and AT1R 1166C alleles on the risk of preeclampsia and observed a higher frequency of both alleles in preeclamptic patients (26.5%) than that in controls (24.4%) but it did not reach statistical significance (<italic>p</italic>=0.78).</p>
<p>The levels of MDA and TAC in different genotypes of ACE I/D and AT1R A1166C in patients and controls are presented in <xref ref-type="table" rid="table5-1470320312448950">Table 5</xref>.</p>
<table-wrap id="table5-1470320312448950" position="float">
<label>Table 5.</label>
<caption>
<p>The levels of MDA and TAC in various genotypes of AT1R and ACE in mild and severe preeclamptic women compared to those in controls.</p>
</caption>
<graphic alternate-form-of="table5-1470320312448950" xlink:href="10.1177_1470320312448950-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">AT1R genotypes</th>
<th align="left">Mild preeclampsia</th>
<th align="left">Severe preeclampsia</th>
<th align="left">Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td><italic>n</italic>=82</td>
<td><italic>n</italic>=46</td>
<td><italic>n</italic>=66</td>
</tr>
<tr>
<td>MDA (µM)</td>
<td><xref ref-type="table-fn" rid="table-fn5-1470320312448950">*</xref>8.5±2.6</td>
<td><xref ref-type="table-fn" rid="table-fn5-1470320312448950">*</xref>12.8±4.5</td>
<td>5.6±1.7</td>
</tr>
<tr>
<td>TAC (mM)</td>
<td>1.36±0.26</td>
<td>1.39±0.2</td>
<td>1.4 ±0.18</td>
</tr>
<tr>
<td>AC</td>
<td><italic>n</italic>=37</td>
<td><italic>n</italic>=13</td>
<td><italic>n</italic>=20</td>
</tr>
<tr>
<td>MDA (µM)</td>
<td><xref ref-type="table-fn" rid="table-fn5-1470320312448950">*</xref>8.6±2.4</td>
<td><xref ref-type="table-fn" rid="table-fn5-1470320312448950">*</xref>13.6±4.7</td>
<td>6.3±2.7</td>
</tr>
<tr>
<td>TAC (mM)</td>
<td>1.30±0.21</td>
<td>1.33±0.18</td>
<td>1.42 ±0.09</td>
</tr>
<tr>
<td>CC</td>
<td><italic>n</italic>=3</td>
<td>—</td>
<td><italic>n</italic>=4</td>
</tr>
<tr>
<td>MDA (µM)</td>
<td><xref ref-type="table-fn" rid="table-fn5-1470320312448950">*</xref>9.7±2.9</td>
<td>—</td>
<td>5.1±0.76</td>
</tr>
<tr>
<td>TAC (mM)</td>
<td>1.11±0.28</td>
<td>—</td>
<td>1.39 ±0.18</td>
</tr>
<tr>
<td>ACE genotypes</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>II</td>
<td><italic>n</italic>=14</td>
<td><italic>n</italic>=11</td>
<td><italic>n</italic>=16</td>
</tr>
<tr>
<td>MDA (µM)</td>
<td><xref ref-type="table-fn" rid="table-fn5-1470320312448950">*</xref>8.7±2.8</td>
<td><xref ref-type="table-fn" rid="table-fn5-1470320312448950">*</xref>15.4±5.5</td>
<td>5.3±1.5</td>
</tr>
<tr>
<td>TAC (mM)</td>
<td>1.45±0.15</td>
<td>1.37±0.23</td>
<td>1.43 ±0.18</td>
</tr>
<tr>
<td>ID</td>
<td><italic>n</italic>=32</td>
<td><italic>n</italic>=16</td>
<td><italic>n</italic>=42</td>
</tr>
<tr>
<td>MDA (µM)</td>
<td><xref ref-type="table-fn" rid="table-fn5-1470320312448950">*</xref>8.4±2.3</td>
<td><xref ref-type="table-fn" rid="table-fn5-1470320312448950">*</xref>12.3±3.9</td>
<td>6.2±2.7</td>
</tr>
<tr>
<td>TAC (mM)</td>
<td><xref ref-type="table-fn" rid="table-fn5-1470320312448950">*</xref>, #1.25±0.29</td>
<td>1.43±0.13</td>
<td>1.38 ±0.2</td>
</tr>
<tr>
<td>DD</td>
<td><italic>n</italic>=82</td>
<td><italic>n</italic>=43</td>
<td><italic>n</italic>=40</td>
</tr>
<tr>
<td>MDA (µM)</td>
<td><xref ref-type="table-fn" rid="table-fn5-1470320312448950">*</xref>8.6±2.5</td>
<td><xref ref-type="table-fn" rid="table-fn5-1470320312448950">*</xref>13±4.6</td>
<td>5.7±1.8</td>
</tr>
<tr>
<td>TAC (mM)</td>
<td>1.34±0.23</td>
<td>1.36±0.2</td>
<td>1.37 ±0.13</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-1470320312448950">
<label>*</label>
<p><italic>p</italic>&lt; 0.05 compared to controls; <sup>#</sup><italic>p</italic>&lt; 0.05 compared to ACE II genotype; MDA: malondialdehyde; TAC: total antioxidant capacity; AT1R: angiotensin II type-1 receptor; ACE: angiotensin converting enzyme.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>For all of the ACE I/D genotypes the MDA level was significantly higher in patients compared to controls. However, the TAC level was not significantly different between patients and controls. In mild preeclamptic women carrying ID genotype, the level of TAC was significantly lower compared to the controls with the same genotype. A similar result was detected for AT1R A1166C polymorphism (<xref ref-type="table" rid="table5-1470320312448950">Table 5</xref>). Comparison of genotypes within each group indicated that in mild preeclamptic women with the ID genotype the level of TAC was significantly (<italic>p</italic>=0.025) decreased compared to those with II genotype. Also, there was a trend toward increasing MDA and decreasing TAC levels from AT1R AA to CC genotype in mild and severe preeclamptic women.</p>
<p>In preeclamptic women with early-onset preeclampsia, the frequency of ID+DD genotypes (91.3%) was higher than in late-onset preeclamptic women (86.9%) but their difference was not significant (<italic>p</italic>=0.54).</p>
<sec id="section12-1470320312448950">
<title>The generalized odds ratio (OR<sub>G</sub>)</title>
<p>In the present study the OR<sub>G</sub> for association of ACE I/D polymorphism and preeclampsia was 1.53 (95% CI=1.08–2.16), meaning that individuals who are homozygous for D allele have the highest mutational load, those homozygous for I allele have the lowest, and those who are heterozygous have an intermediate level. Then, for any two subjects, with and without preeclampsia, the probability of having preeclampsia is 53% higher (relative to the probability of lacking preeclampsia) given that the diseased subject has a higher mutational load than the healthy one.</p>
</sec>
</sec>
<sec id="section13-1470320312448950" sec-type="discussion">
<title>Discussion</title>
<p>The fact that during pregnancy, in spite of a two-fold increase in angiotensin II level, pregnant women remain normotensive, could be attributed to resistance to the angiotensin II presser effects and down-regulation of the AT1R receptor.<sup><xref ref-type="bibr" rid="bibr25-1470320312448950">25</xref></sup> In preeclampsia, perturbation of the renin-angiotensin system is associated with an increased vascular responsiveness to angiotensin II.<sup><xref ref-type="bibr" rid="bibr26-1470320312448950">26</xref></sup></p>
<p>Our present study indicated an association between ACE I/D polymorphism and a 1.89-fold increased risk of preeclampsia in the presence of DD genotype. This association could be explained by higher ACE activity in the presence of DD genotype, resulting in an increased angiotensin II level that causes an inflammatory response.<sup><xref ref-type="bibr" rid="bibr27-1470320312448950">27</xref></sup> It has been suggested that in some populations the D allele, by elevating ACE activity and in the presence of various environmental variables, may be associated with hypertension.<sup><xref ref-type="bibr" rid="bibr28-1470320312448950">28</xref></sup> Also, the ACE I/D polymorphism is involved in the modulation of maternal uteroplacental and fetal umbilical flows.<sup><xref ref-type="bibr" rid="bibr27-1470320312448950">27</xref></sup></p>
<p>We did not detect an association between AT1R A1166C polymorphism and the risk of preeclampsia in Western Iran. It has been suggested that AT1R A1166C gene polymorphism has no effect on receptor function or density, although it may alter sensitivity to angiotensin.<sup><xref ref-type="bibr" rid="bibr28-1470320312448950">28</xref></sup></p>
<p>The frequency of ACE I/D and AT1R A1166C alleles and genotypes and their possible associations with the risk of preeclampsia have been investigated in different populations. Most of the studies reported the absence of an association between these polymorphisms and the risk of preeclampsia. In Korean and Colombian populations, the ACE I/D polymorphism<sup><xref ref-type="bibr" rid="bibr1-1470320312448950">1</xref>,<xref ref-type="bibr" rid="bibr3-1470320312448950">3</xref></sup> was not associated with the pathogenesis of preeclampsia. Also, in Greek and Black South African women<sup><xref ref-type="bibr" rid="bibr8-1470320312448950">8</xref>,<xref ref-type="bibr" rid="bibr10-1470320312448950">10</xref></sup> neither ACE I/D nor AT1R A1166C variants were independently and directly associated with the risk of preeclampsia/eclampsia. In addition, there is a report of lack of association between AT1R A1166C polymorphism and preeclampsia in Afro-Caribbean, Asian and Caucasian populations.<sup><xref ref-type="bibr" rid="bibr9-1470320312448950">9</xref></sup> Finally, in a recent meta-analysis by Shaik et al.<sup><xref ref-type="bibr" rid="bibr11-1470320312448950">11</xref></sup> using data from 17 studies, the presence of ACE I/D polymorphism was not associated with increased risk of preeclampsia. In contrast, there are a few studies indicating that ACE I/D polymorphism might have a role in complications of pregnancy, including preeclampsia. In studies from South Eastern Iran,<sup><xref ref-type="bibr" rid="bibr12-1470320312448950">12</xref></sup> Northern India<sup><xref ref-type="bibr" rid="bibr13-1470320312448950">13</xref></sup> and Turkey,<sup><xref ref-type="bibr" rid="bibr15-1470320312448950">15</xref></sup> the presence of D allele of ACE was associated with increased risk of preeclampsia.<sup><xref ref-type="bibr" rid="bibr12-1470320312448950">12</xref></sup> The study by Uma et al.<sup><xref ref-type="bibr" rid="bibr14-1470320312448950">14</xref></sup> suggested an association between the DD genotype of the ACE gene and early-onset preeclampsia. Also, Kaur et al.<sup><xref ref-type="bibr" rid="bibr4-1470320312448950">4</xref></sup> reported that the ACE DD genotype is a potent risk factor for the development of hypertension during pregnancy. Furthermore, in a meta-analysis by Chen et al.<sup><xref ref-type="bibr" rid="bibr16-1470320312448950">16</xref></sup> including 30 case-control studies the DD genotype of ACE was significantly associated with increased risk of pregnancy hypertensive disorders, especially among Asian and Caucasians. These inconsistent results of the effect of ACE I/D and AT1R A1166C variants on the risk of preeclampsia in different studies could be attributed to different ethnicities, sample size, defining preeclampsia criteria and gene-environment interactions.</p>
<p>In our study ACE D allele and DD genotype were associated with increased risk of mild preeclampsia (1.99- and 2.34-fold, respectively) compared to severe preeclampsia (1.61- and 1.56-fold, respectively). Similarly, Mandò et al.<sup><xref ref-type="bibr" rid="bibr29-1470320312448950">29</xref></sup> reported different distributions of ACE genotypes in mild preeclampsia but not in the severe form. They suggested that different factors may lead to mild and severe preeclampsia, and ACE I/D polymorphism may play a more important role in the mild form.</p>
<p>Inappropriate activation of the RAAS and disturbances of uteroplacental circulation might be involved in the development of preeclampsia.<sup><xref ref-type="bibr" rid="bibr3-1470320312448950">3</xref>,<xref ref-type="bibr" rid="bibr30-1470320312448950">30</xref></sup> In the study by Bukreeva et al.,<sup><xref ref-type="bibr" rid="bibr30-1470320312448950">30</xref></sup> ACE I/D genotype was significantly associated with the history of fetal loss and suggested an involvement of the RAAS in pregnancy complications. Also, the contribution of the RAAS genes including ACE I/D polymorphism in mothers and newborns in the pathogenesis of preeclampsia has been suggested.<sup><xref ref-type="bibr" rid="bibr31-1470320312448950">31</xref></sup></p>
<p>In some studies the synergistic effect of RAAS gene variants including angiotensinogen (AGT) M235T with ACE I/D or AT1R A1166C has been examined in preeclampsia and a significant interaction between AGT M235T and ACE I/D polymorphisms on the risk of preeclampsia has been reported.<sup><xref ref-type="bibr" rid="bibr8-1470320312448950">8</xref></sup> However, the authors did not investigate the interaction between ACE I/D and AT1R A1166C polymorphisms in their study because of the lack of association of each polymorphism separately with the risk of preeclampsia. Our present study demonstrated lack of synergistic effect between two alleles of ACE D and AT1R 1166C on the risk of preeclampsia.</p>
<p>There is a biochemical imbalance in preeclampsia that is associated with an increase of oxidative stress and lipid peroxidation and, at the same time, a deficient antioxidant protection.<sup><xref ref-type="bibr" rid="bibr18-1470320312448950">18</xref></sup> The findings of the present study demonstrate that the ID genotype of ACE is associated with lower TAC level compared to the II genotype. It has been suggested that the DD genotype of ACE I/D polymorphism might be involved in the pathogenesis of preeclampsia through elevation in lipid peroxidation and reduction in antioxidant capacity.<sup><xref ref-type="bibr" rid="bibr32-1470320312448950">32</xref></sup> These abnormalities may result in endothelial injury, placental hypoxia or the interaction with hypertensive disease and atherosclerosis, as suggested by Kobashi et al.<sup><xref ref-type="bibr" rid="bibr33-1470320312448950">33</xref></sup></p>
<p>Briefly, the present study indicates significantly higher levels of MDA in preeclamptic patients than controls. Also, we detected an association between ACE I/D polymorphism and the risk of preeclampsia. It is possible that lipid peroxidation and oxidative stress are involved in the pathogenesis of preeclampsia in our sample and that might be influenced by polymorphism in the genes of the renin-angiotensin-aldosterone system.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>None declared.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This work was supported by a grant from Kermanshah University of Medical Sciences, office of Vice Chancellor for Research, Kermanshah, Iran, (grant number 89021).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1470320312448950">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>YJ</given-names></name>
<name><surname>Park</surname><given-names>MH</given-names></name>
<name><surname>Park</surname><given-names>HS</given-names></name><etal/>
</person-group>. <article-title>Associations of polymorphisms of the angiotensinogen M235 polymorphism and angiotensin-converting-enzyme intron 16 insertion/deletion polymorphism with preeclampsia in Korean women</article-title>. <source>Eur J Obstet Gyn R B</source> <year>2004</year>; <volume>116</volume>: <fpage>48</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr2-1470320312448950">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaiser</surname><given-names>T</given-names></name>
<name><surname>Brennecke</surname><given-names>SP</given-names></name>
<name><surname>Moses</surname><given-names>EK</given-names></name>
</person-group>. <article-title>C677T methylenetetrahydrofolate reductase polymorphism is not a risk factor for pre-eclampsia/eclampsia among Australian women</article-title>. <source>Hum Hered</source> <year>2001</year>; <volume>51</volume>: <fpage>20</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr3-1470320312448950">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Serrano</surname><given-names>NC</given-names></name>
<name><surname>Diaz</surname><given-names>LA</given-names></name>
<name><surname>Paez</surname><given-names>MC</given-names></name><etal/>
</person-group>. <article-title>Angiotensin-converting enzyme I/D polymorphism and preeclampsia risk: evidence of small-study bias</article-title>. <source>PLoS Med</source> <year>2006</year>; <volume>3</volume>: <fpage>e520</fpage></citation>
</ref>
<ref id="bibr4-1470320312448950">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaur</surname><given-names>R</given-names></name>
<name><surname>Jain</surname><given-names>V</given-names></name>
<name><surname>Khuller</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Association of angiotensin-converting enzyme gene polymorphism with pregnancy-induced hypertension</article-title>. <source>Acta Obstet Gynecol Scand</source> <year>2005</year>: <volume>84</volume>: <fpage>929</fpage>–<lpage>933</lpage>.</citation>
</ref>
<ref id="bibr5-1470320312448950">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Velloso</surname><given-names>EP</given-names></name>
<name><surname>Vieira</surname><given-names>R</given-names></name>
<name><surname>Cabral</surname><given-names>AC</given-names></name><etal/>
</person-group>. <article-title>Reduced plasma levels of angiotensin-(1-7) and renin activity in preeclamptic patients are associated with the angiotensin I converting enzyme deletion/ deletion genotype</article-title>. <source>Braz J Med Biol Res</source> <year>2007</year>; <volume>40</volume>: <fpage>583</fpage>–<lpage>590</lpage>.</citation>
</ref>
<ref id="bibr6-1470320312448950">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rahimi</surname><given-names>Z</given-names></name>
<name><surname>Vaisi-Raygani</surname><given-names>A</given-names></name>
<name><surname>Rahimi</surname><given-names>Z</given-names></name><etal/>
</person-group>. <article-title>The concomitant presence of eNOS 894T and ACE D alleles are associated with diabetic nephropathy in a Kurdish population from Western Iran</article-title>. <source>Nephrology</source> <year>2012</year>; <volume>17</volume>: <fpage>175</fpage>–<lpage>181</lpage>.</citation>
</ref>
<ref id="bibr7-1470320312448950">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Felehgari</surname><given-names>V</given-names></name>
<name><surname>Rahimi</surname><given-names>Z</given-names></name>
<name><surname>Mozafari</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>ACE gene polymorphism and serum ACE activity in Iranians type II diabetic patients with macroalbuminuria</article-title>. <source>Mol Cell Biochem</source> <year>2011</year>; <volume>346</volume>: <fpage>23</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr8-1470320312448950">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bouba</surname><given-names>I</given-names></name>
<name><surname>Makrydimas</surname><given-names>G</given-names></name>
<name><surname>Kalaitzidis</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Interaction between the polymorphisms of the renin-angiotensin system in preeclampsia</article-title>. <source>Eur J Obstet Gyn R B</source> <year>2003</year>; <volume>110</volume>: <fpage>8</fpage>–<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr9-1470320312448950">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Akbar</surname><given-names>SA</given-names></name>
<name><surname>Khawaja</surname><given-names>NP</given-names></name>
<name><surname>Brown</surname><given-names>PR</given-names></name><etal/>
</person-group>. <article-title>Angiotensin II type 1 and 2 receptors polymorphisms in pre-eclampsia and normal pregnancy in three different populations</article-title>. <source>Acta Obstet Gynecol Scand</source> <year>2009</year>; <volume>88</volume>: <fpage>606</fpage>–<lpage>611</lpage>.</citation>
</ref>
<ref id="bibr10-1470320312448950">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roberts</surname><given-names>CB</given-names></name>
<name><surname>Rom</surname><given-names>L</given-names></name>
<name><surname>Moodley</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Hypertension-related gene polymorphisms in pre-eclampsia, eclampsia and gestational hypertension in Black South African women</article-title>. <source>J Hypertens</source> <year>2004</year>; <volume>22</volume>: <fpage>945</fpage>–<lpage>948</lpage>.</citation>
</ref>
<ref id="bibr11-1470320312448950">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shaik</surname><given-names>AP</given-names></name>
<name><surname>Sultana</surname><given-names>A</given-names></name>
<name><surname>Bammidi</surname><given-names>VK</given-names></name><etal/>
</person-group>. <article-title>A meta-analysis of eNOS and ACE gene polymorphisms and risk of pre-eclampsia in women</article-title>. <source>J Obstet Gynaecol</source> <year>2011</year>; <volume>31</volume>: <fpage>603</fpage>–<lpage>607</lpage>.</citation>
</ref>
<ref id="bibr12-1470320312448950">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Salimi</surname><given-names>S</given-names></name>
<name><surname>Mokhtari</surname><given-names>M</given-names></name>
<name><surname>Yaghmaei</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Association of angiotensin-converting enzyme intron 16 insertion/deletion and angiotensin II type 1 receptor A1166C gene polymorphisms with preeclampsia in South East of Iran</article-title>. <source>J Biomed Biotechnol</source> <year>2011</year>; <volume>2011</volume>: <fpage>941515</fpage>.</citation>
</ref>
<ref id="bibr13-1470320312448950">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aggarwal</surname><given-names>S</given-names></name>
<name><surname>Dimri</surname><given-names>N</given-names></name>
<name><surname>Tandon</surname><given-names>I</given-names></name><etal/>
</person-group>. <article-title>Preeclampsia in North Indian women: the contribution of genetic polymorphisms</article-title>. <source>J Obstet Gynaecol Res</source> <year>2011</year>; <volume>37</volume>: <fpage>1335</fpage>–<lpage>1341</lpage>.</citation>
</ref>
<ref id="bibr14-1470320312448950">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Uma</surname><given-names>R</given-names></name>
<name><surname>Forsyth</surname><given-names>SJ</given-names></name>
<name><surname>Struthers</surname><given-names>AD</given-names></name><etal/>
</person-group>. <article-title>Polymorphisms of the angiotensin converting enzyme gene in early-onset and late-onset pre-eclampsia</article-title>. <source>J Matern Fetal Neonatal Med</source> <year>2010</year>; <volume>23</volume>: <fpage>874</fpage>–<lpage>879</lpage>.</citation>
</ref>
<ref id="bibr15-1470320312448950">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gurdol</surname><given-names>F</given-names></name>
<name><surname>Isbilen</surname><given-names>E</given-names></name>
<name><surname>Yilmaz</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>The association between preeclampsia and angiotensin-converting enzyme insertion/deletion polymorphism</article-title>. <source>Clin Chim Acta</source> <year>2004</year>; <volume>341</volume>: <fpage>127</fpage>–<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr16-1470320312448950">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Z</given-names></name>
<name><surname>Xu</surname><given-names>F</given-names></name>
<name><surname>Wei</surname><given-names>Y</given-names></name><etal/>
</person-group>. <article-title>Angiotensin converting enzyme insertion/deletion polymorphism and risk of pregnancy hypertensive disorders: a meta-analysis</article-title>. <source>J Renin Angiotensin Sys</source> <year>2012</year>; <volume>13</volume>: <fpage>184</fpage>–<lpage>195</lpage>.</citation>
</ref>
<ref id="bibr17-1470320312448950">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Szolnoki</surname><given-names>Z</given-names></name>
<name><surname>Havasi</surname><given-names>V</given-names></name>
<name><surname>Talián</surname><given-names>G</given-names></name><etal/>
</person-group>. <article-title>Angiotensin II type-1 receptor A1166C polymorphism is associated with increased risk of ischemic stroke in hypertensive smokers</article-title>. <source>J Mol Neuroscience</source> <year>2006</year>; <volume>28</volume>: <fpage>285</fpage>–<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr18-1470320312448950">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chamy</surname><given-names>VM</given-names></name>
<name><surname>Lepe</surname><given-names>J</given-names></name>
<name><surname>Cataln</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Oxidative stress is closely related to clinical severity of pre-eclampsia</article-title>. <source>Biol Res</source> <year>2006</year>; <volume>39</volume>: <fpage>229</fpage>–<lpage>236</lpage>.</citation>
</ref>
<ref id="bibr19-1470320312448950">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malek-Khosravi</surname><given-names>S</given-names></name>
<name><surname>Rahimi</surname><given-names>Z</given-names></name>
<name><surname>Rahimi</surname><given-names>Z</given-names></name><etal/>
</person-group>. <article-title>Thrombophilic mutations and susceptibility to preeclapmsia in Western Iran</article-title>. <source>J Thromb Thrombolysis</source> <year>2012</year>; <volume>33</volume>: <fpage>109</fpage>-<lpage>115</lpage>.</citation>
</ref>
<ref id="bibr20-1470320312448950">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sibai</surname><given-names>BM</given-names></name>
<name><surname>Stella</surname><given-names>CL</given-names></name>
</person-group>. <article-title>Diagnosis and management of atypical preeclampsia-eclampsia</article-title>. <source>Am J Obstet Gynecol</source> <year>2009</year>; <volume>200</volume>: <fpage>e1</fpage>-<lpage>e7</lpage>.</citation>
</ref>
<ref id="bibr21-1470320312448950">
<label>21.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Old</surname><given-names>JM</given-names></name>
<name><surname>Higgs</surname><given-names>DR</given-names></name>
</person-group>. <article-title>Gene analysis</article-title>. In: <person-group person-group-type="editor">
<name><surname>Weatherall</surname><given-names>DJ</given-names></name>
</person-group> (ed) <source>Methods in hematology</source>, <volume>vol. 6</volume>. The thalassemias. <publisher-loc>London</publisher-loc>: <publisher-name>Churchill Livingstone</publisher-name>, <year>1983</year>, pp. <fpage>74</fpage>–<lpage>101</lpage>.</citation>
</ref>
<ref id="bibr22-1470320312448950">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rahimi</surname><given-names>Z</given-names></name>
<name><surname>Felehgari</surname><given-names>V</given-names></name>
<name><surname>Rahimi</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria</article-title>. <source>Mol Biol Rep</source> <year>2011</year>; <volume>38</volume>: <fpage>2117</fpage>–<lpage>2123</lpage>.</citation>
</ref>
<ref id="bibr23-1470320312448950">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Agarwal</surname><given-names>R</given-names></name>
</person-group>. <article-title>Rapid fluorimetric-liquid chromatographic determination of malodialdehyde in biological samples</article-title>. <source>J Chromatography B</source> <year>2002</year>; <volume>775</volume>: <fpage>121</fpage>-<lpage>126</lpage>.</citation>
</ref>
<ref id="bibr24-1470320312448950">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zintzaras</surname><given-names>E</given-names></name>
</person-group>. <article-title>The generalized odds ratio as a measure of genetic risk effect in the analysis and meta-analysis of association studies</article-title>. <source>Stat Appl Genet Mol Biol</source> <year>2010</year>; <volume>9</volume>: <fpage>1</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr25-1470320312448950">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brosnihan</surname><given-names>KB</given-names></name>
<name><surname>Neves</surname><given-names>LAA</given-names></name>
<name><surname>Anton</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Enhanced expression of Ang-(1-7) during pregnancy</article-title>. <source>Braz J Med Biol Res</source> <year>2004</year>; <volume>37</volume>: <fpage>1255</fpage>–<lpage>1262</lpage>.</citation>
</ref>
<ref id="bibr26-1470320312448950">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ringholm</surname><given-names>L</given-names></name>
<name><surname>Pedersen-Bjergaard</surname><given-names>U</given-names></name>
<name><surname>Thorsteinsson</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>A high concentration of prorenin in early pregnancy is associated with development of pre-eclampsia in women with type 1 diabetes</article-title>. <source>Diabetologia</source> <year>2011</year>; <volume>54</volume>: <fpage>1615</fpage>–<lpage>1619</lpage>.</citation>
</ref>
<ref id="bibr27-1470320312448950">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mello</surname><given-names>G</given-names></name>
<name><surname>Parretti</surname><given-names>E</given-names></name>
<name><surname>Gensini</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>Maternal-fetal flow, negative events, and preeclampsia: role of ACE I/D polymorphism</article-title>. <source>Hypertension</source> <year>2003</year>; <volume>41</volume>: <fpage>932</fpage>–<lpage>937</lpage>.</citation>
</ref>
<ref id="bibr28-1470320312448950">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gard</surname><given-names>PR</given-names></name>
</person-group>. <article-title>Implications of the angiotensin converting enzyme gene insertion/deletion polymorphism in health and disease: a snapshot review</article-title>. <source>Int J Mol Epidemiol Genet</source> <year>2010</year>; <volume>1</volume>: <fpage>145</fpage>-<lpage>157</lpage>.</citation>
</ref>
<ref id="bibr29-1470320312448950">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mandò</surname><given-names>C</given-names></name>
<name><surname>Antonazzo</surname><given-names>P</given-names></name>
<name><surname>Tabano</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Angiotensin-converting enzyme and adducin-1 polymorphisms in women with preeclampsia and gestational hypertension</article-title>. <source>Reprod Sci</source> <year>2009</year>; <volume>16</volume>: <fpage>819</fpage>–<lpage>826</lpage>.</citation>
</ref>
<ref id="bibr30-1470320312448950">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bukreeva</surname><given-names>L</given-names></name>
<name><surname>Grigorov</surname><given-names>A</given-names></name>
<name><surname>Kiesewetter</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>Association of angiotensin-converting enzyme intron 16 insertion/deletion polymorphism with history of foetal loss</article-title>. <source>J Renin Angiotensin Aldosterone Syst</source> <year>2009</year>; <volume>10</volume>: <fpage>237</fpage>–<lpage>240</lpage>.</citation>
</ref>
<ref id="bibr31-1470320312448950">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Procopciuc</surname><given-names>LM</given-names></name>
<name><surname>Caracostea</surname><given-names>G</given-names></name>
<name><surname>Zaharie</surname><given-names>G</given-names></name><etal/>
</person-group>. <article-title>Maternal/newborn genotype contribution of the renin-angiotensin system (Met235Thr, Thr174Met, I/D-ACE, A2350G-ACE, A1166C-AT2R1, C3123A- AT2R2, 83A/G-REN) to the risk of pre-eclampsia: a Romanian study</article-title>. <source>J Renin Angiotensin Aldosterone Syst</source> <year>2011</year>; <volume>12</volume>: <fpage>539</fpage>–<lpage>548</lpage>.</citation>
</ref>
<ref id="bibr32-1470320312448950">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>D</given-names></name>
<name><surname>Trivedi</surname><given-names>SS</given-names></name>
<name><surname>Bhattacharjee</surname><given-names>J</given-names></name>
</person-group>. <article-title>Oxidative stress and eNOS (Glu298Asp) gene polymorphism in preeclampsia in Indian population</article-title>. <source>Mol Cell Biochem</source> <year>2011</year>; <volume>353</volume>: <fpage>189</fpage>-<lpage>193</lpage>.</citation>
</ref>
<ref id="bibr33-1470320312448950">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kobashi</surname><given-names>G</given-names></name>
<name><surname>Hata</surname><given-names>A</given-names></name>
<name><surname>Shido</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>Insertion/deletion polymorphism of the angiotensin-converting enzyme gene and preeclampsia in Japanese patients</article-title>. <source>Semin Thromb Hemost</source> <year>2005</year>; <volume>31</volume>: <fpage>346</fpage>–<lpage>350</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>